NuCana plc (NCNA)
NCNA Stock Price Chart
Explore NuCana plc interactive price chart. Choose custom timeframes to analyze NCNA price movements and trends.
NCNA Company Profile
Discover essential business fundamentals and corporate details for NuCana plc (NCNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Sept 2017
Employees
20.00
Website
https://www.nucana.comCEO
Hugh Stephen Griffith
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
NCNA Financial Timeline
Browse a chronological timeline of NuCana plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 1 Jun 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 24 Nov 2025
Earnings released on 20 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$2.75 by +94.17%.
Stock split effective on 8 Aug 2025
Shares were split 1 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Jun 2025
EPS came in at -$126.00 falling short of the estimated -$2.58 by -4.78K%.
Earnings released on 20 Mar 2025
EPS came in at -$64.00 surpassing the estimated -$486.00 by +86.83%.
Earnings released on 25 Nov 2024
EPS came in at -$456.00 falling short of the estimated -$3.47 by -13.04K%.
Earnings released on 15 Aug 2024
EPS came in at -$758.00 falling short of the estimated -$710.00 by -6.76%.
Earnings released on 16 May 2024
EPS came in at -$32.00 surpassing the estimated -$662.00 by +95.17%.
Stock split effective on 16 Apr 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 Mar 2024
EPS came in at -$850.00 falling short of the estimated -$650.00 by -30.77%.
Earnings released on 16 Nov 2023
EPS came in at -$800.00 falling short of the estimated -$650.00 by -23.08%.
Earnings released on 16 Aug 2023
EPS came in at -$650.00 surpassing the estimated -$800.00 by +18.75%.
Earnings released on 17 May 2023
EPS came in at -$900.00 falling short of the estimated -$600.00 by -50.00%.
Earnings released on 4 Apr 2023
EPS came in at -$0.07 .
Earnings released on 16 Nov 2022
EPS came in at -$550.00 surpassing the estimated -$650.00 by +15.38%.
Earnings released on 17 Aug 2022
EPS came in at -$450.00 surpassing the estimated -$700.00 by +35.71%.
Earnings released on 2 Jun 2022
EPS came in at -$1.05K falling short of the estimated -$950.00 by -10.53%.
Earnings released on 27 Apr 2022
EPS came in at -$0.14 .
Earnings released on 18 Nov 2021
EPS came in at -$1.05K surpassing the estimated -$1.25K by +16.00%.
Earnings released on 19 Aug 2021
EPS came in at -$1.20K matching the estimated -$1.20K.
Earnings released on 19 May 2021
EPS came in at -$1.30K falling short of the estimated -$1.10K by -18.18%.
Earnings released on 4 Mar 2021
EPS came in at -$1.60K falling short of the estimated -$1.05K by -52.38%.
Earnings released on 19 Nov 2020
EPS came in at -$1.55K falling short of the estimated -$1.20K by -29.17%.
NCNA Stock Performance
Access detailed NCNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.